ASTROCYTOMA, IDH-MUTANT, GRADE 2

Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.

Never miss a new study

Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear

Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1

New hope for brain cancer patients in Early-Stage trial

Disease control Ongoing

This early-stage trial is testing a new drug called telaglenastat, given alongside standard radiation and chemotherapy (temozolomide), for people with certain types of brain tumors (IDH-mutant astrocytomas). The main goals are to find the safest dose of the new drug combination a…

Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 17, 2026 13:09 UTC

ASTROCYTOMA, IDH-MUTANT, GRADE 2

Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear

New hope for brain cancer patients in Early-Stage trial